{"entity":{"id":"nct07559929","kind":"trial","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","aka":[],"tldr":"A phase 1/2 trial of toripalimab, carboplatin and cisplatin in lung cancer, run by Hangzhou DAC Biotechnology Co., Ltd., now recruiting.","summary":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. is a phase 1/2, interventional study registered as NCT07559929 by Hangzhou DAC Biotechnology Co., Ltd., with a registry enrolment figure of 200 participants, started 2026-08-19 and due to reach its primary completion in 2028-06-01. Interventions recorded: DXC006; Toripalimab; Carboplatin; Cisplatin. Conditions listed: Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS); 6-month progression-free survival rate; Recommended Phase 2 Dose (RP2D). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed small cell lung cancer (SCLC)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07559929","url":"https://clinicaltrials.gov/study/NCT07559929"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["toripalimab","carboplatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07559929","phase":"1/2","setting":"A Phase Ib/II Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.","sponsor":"Hangzhou DAC Biotechnology Co., Ltd.","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07559929/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}